Healthcare Group
Realising the Potential of Precision Medicine
Wednesday 8 November, 18:30 for 19:00 – 21:30
This event is supported by IQVIA
Precision Medicine – the power to more accurately predict which treatment and prevention strategies will work best for a particular patient – holds tremendous potential to transform patient care and outcomes. But realising the potential of precision medicines presents significant challenges to companies developing innovative treatments, health systems seeking to understand how to transform
clinical practice, payers trying to work out how to prioritise increasingly limited budgets and life science companies seeking to deliver patient benefit whilst maintaining meaningful returns for their investors and sustaining their investment in innovation. It also requires a systematic approach to harnessing the power of data to inform treatment and outcomes.
Join us as we explore the potential for precision medicine – and the challenges of realising that potential with our hugely experienced panel:
Oliver Backhouse is currently VP Strategic Partnerships, Digital Health R&D; previously VP, Precision Medicine and Genomics R&D at AstraZeneca. Oliver has worked in R&D at AstraZeneca for the last six years, initially heading strategy in Precision Medicine and Genomics and currently responsible for Reimagining Healthcare in Digital Health. Prior to this at AZ, Oliver was in Commercial where he was the Country President in Malaysia/Singapore and led the antibiotics franchise globally. Before AZ, Oliver had periods at Chiron, McKinsey, the UK Prime Minister’s Office and GSK. He has an MBA from HBS and MA/BAs in cancer biology and mathematics.
Dr Claire Bloomfield is Director of NHS England’s Centre for Improving Data Collaboration. Claire oversees development and delivery of NHSE’s Transformation Directorate’s coordinated investments in health data for R&D, to support the ambitions of the Life Sciences Vision, the Vision for Future of UK Clinical Research Delivery and Genome UK. Previously, Claire was Head of Strategy and Innovation for the Cancer Research UK and then CEO for the UK National Consortium of Intelligent Medical Imaging. Her interest in health data research focuses on supporting the ecosystem to develop effective collaborations and ensuring equity and diversity in healthcare innovation to improve care.
Veronique Bouchet (MBA 94D), is Chief Medical Officer at Precision Life Ltd, a UK based precision medicine company. With over 30 years’ experience in the healthcare industry, she has held a variety of senior international roles across several therapeutic areas and functions, including drug development, business development, corporate and venture strategy at AstraZeneca in the UK and Gruenenthal GmbH in Germany, as well as investment management. Veronique was recognised as one of 50 Movers and Shakers challenging the status quo to bring better health in BioBusiness 2019.
Joanne M. Hackett is Vice President and Head of Genomic and Precision Medicine at IQVIA and previously was the Chief Commercial Officer at Genomics England. Joanne is a clinical academic, entrepreneur, investor, and a strategic, creative visionary with global experience spanning successful start-ups to Fortune 500 companies. She is known for building innovation, driving personalised medicine and leading through fast paced, complex changing ecosystems and integrations. Joanne has been publicly recognised through a number of awards. Joanne’s goal is to contribute to bringing the world novel, cost effective and simple health care solutions, and she is particularly keen on building the case for prevention, open science and citizen genomics.
CLICK HERE TO BOOK VIA MYINSEAD
(Members will need to enter a promo code to access discounted tickets – contact [email protected] for details)